New Gene Therapy Approach Transforms Scar-Forming Astrocytes Into Working Motor Neurons

Scientists have reported a new strategy for coaxing one of the brain’s most stubborn cell types to change its identity in a way that could reshape how researchers think about repairing the damaged nervous system. In a study published in Experimental & Molecular Medicine, a research team describes an approach called TRANsCre-DIONE, which converts scar-forming reactive astrocytes into cells that display the defining features of functional motor neurons. The work addresses one of the central obstacles in regenerative neurobiology: the scar tissue that forms after injury to the brain or spinal cord is packed with reactive astrocytes, cells that normally protect the wounded area but also form a barrier that neurons cannot easily cross or replace.

Astrocytes are the most abundant glial cells in the central nervous system, and in the healthy brain they perform a long list of housekeeping duties. They regulate the chemical environment around synapses, supply metabolic support to neurons, recycle neurotransmitters, and help maintain the blood-brain barrier. When injury, stroke, or neurodegenerative disease strikes, however, astrocytes undergo a dramatic transformation. They hypertrophy, proliferate, and secrete extracellular matrix molecules, forming a dense glial scar. This scar has a dual character. On one hand, it limits inflammation and seals off damaged tissue, preventing the injury from spreading. On the other, it secretes chemical signals that suppress axon regrowth and stands in place of the neurons that were lost. For decades, researchers have debated whether the scar is a friend or an enemy of recovery, and a growing body of work has explored whether the cells inside it could be redirected toward a more useful fate.

The idea of converting glial cells into neurons is not new. Direct lineage reprogramming, or transdifferentiation, forces a differentiated cell to switch identities without passing through an embryonic stem-cell-like state. Earlier studies showed that transcription factors such as NeuroD1, Ascl1, and Ngn2 could push astrocytes, and in some cases reactive astrocytes specifically, toward neuronal fates. In vivo conversion experiments, in which the reprogramming factors were delivered directly into injured brains or spinal cords, generated considerable excitement because they suggested a way to regenerate neurons at the site of damage without transplanting cells. Yet the field has also faced skepticism. Some follow-up studies questioned whether the converted cells were truly derived from astrocytes rather than from a small reservoir of neuronal progenitors, and others found that the induced neurons did not always mature into fully functional circuit elements. Building a method that is both efficient at targeting scar-forming astrocytes and reliable at producing working neurons has remained a significant challenge.

TRANsCre-DIONE, as described in the new report, is designed to meet that challenge head-on. The technique combines genetic targeting elements that drive reprogramming specifically in reactive astrocytes with a factor system that pushes the targeted cells toward a motor neuron identity. The reactive astrocyte specificity matters for two reasons. First, it concentrates the reprogramming machinery where it is needed most, in the scar tissue that accumulates after injury. Second, it minimizes off-target conversion of other cell types, including resting astrocytes that are still performing their normal supportive functions and oligodendrocyte lineage cells that maintain the myelin sheaths around axons. Precision of this kind is a recurring concern in gene therapy approaches to the nervous system, where delivery vehicles cannot always discriminate between neighboring cell populations.

According to the study, the converted cells do not merely adopt a superficial neuronal appearance. The authors report that TRANsCre-DIONE-derived cells acquire molecular signatures characteristic of motor neurons, including expression of marker genes associated with that lineage, and display electrophysiological properties consistent with functional neurons, such as the ability to fire action potentials and form synaptic connections. Functional maturation is the gold standard in the reprogramming field because many induced neurons stall at an immature state, resembling embryonic neurons rather than the specialized adult cell types needed to restore lost functions. Motor neurons in particular carry a heavy burden: they are the final common pathway through which the brain and spinal cord command muscles to contract, and their loss underlies devastating conditions ranging from spinal cord injury to amyotrophic lateral sclerosis.

The implications for motor neuron diseases and spinal cord injury are among the most compelling aspects of the work. In amyotrophic lateral sclerosis, the progressive degeneration of motor neurons leaves scar-forming glia in their wake, and any therapy that could recruit those resident glial cells to replace lost neurons would in principle address both the cell loss and the inhibitory environment at the same time. Similarly, after traumatic spinal cord injury, the lesion core becomes dominated by reactive astrocytes, and converting even a fraction of them into neurons capable of relaying motor commands could help bridge the gap that currently prevents functional recovery. The study’s demonstration that scar-forming cells, rather than a separate progenitor population, can be redirected toward a motor neuron fate speaks directly to this therapeutic vision.

At the same time, the authors and the broader field are careful to note the distance between a laboratory demonstration and a clinical therapy. Delivering reprogramming factors to cells inside the human central nervous system remains a formidable engineering problem. Viral vectors, the most common delivery vehicles, have limited cargo capacity and raise safety questions, particularly when the factors being delivered are transcription factors with the potential to alter cell identity in unintended ways. Researchers must also show that converted neurons integrate appropriately into existing circuits, receive the right inputs, and project to the correct targets, all without provoking immune responses or tumor-like overgrowth. Long-term studies will be needed to confirm that TRANsCre-DIONE-derived motor neurons survive, maintain their identity, and remain functional over the months and years that a real therapy would require.

There are also scientific questions that the new work will likely stimulate. How closely do the induced motor neurons match their endogenous counterparts at the level of gene expression, chromatin state, and connectivity? Do the converted cells retain any memory of their astrocyte origin that might affect their long-term behavior? And can the approach be tuned so that the timing and extent of conversion can be controlled in a living organism, allowing clinicians to modulate the treatment as recovery proceeds? Answers to these questions will determine whether TRANsCre-DIONE becomes a platform technology adaptable to multiple contexts of nervous system damage, or a specialized tool for specific experimental settings. The study adds to a growing consensus, however, that the cells of the glial scar should be viewed not only as obstacles to recovery but also as a locally abundant source of raw material for repair.

What makes the report resonant beyond its immediate technical contribution is the broader shift in perspective it represents. For most of the history of neuroscience, adult central nervous system neurons were considered irreplaceable, and glial scarring was treated as an irreversible endpoint of injury. Over the past decade, that pessimism has given way to a more dynamic view of the injured nervous system, one in which resident cells retain latent developmental programs that can, under the right molecular instructions, be reawakened. TRANsCre-DIONE contributes to this shift by showing that the very cells that barricade a lesion can be instructed to become the neurons needed to restore function. As the team and other groups refine the efficiency, safety, and controllability of such conversions, the prospect of rebuilding neural circuits from within the scar tissue itself moves from science fiction closer to experimental reality, offering a measure of hope to patients whose conditions have long been considered untreatable.

Subject of Research: Direct conversion of scar-forming reactive astrocytes into functional motor neurons using the TRANsCre-DIONE transdifferentiation approach

Article Title: TRANsCre-DIONE transdifferentiates scar-forming reactive astrocytes into functional motor neurons

Article References: An, H., Lee, H.-L., Cho, D.-W., Hong, J., Lee, H. Y., Lee, J. M., Choi, S., Hwang, I.-Y., Woo, J., Lee, J., Park, M., Yang, Y.-S., Han, S.-C., Ha, Y., & Lee, C. J. (2026). TRANsCre-DIONE transdifferentiates scar-forming reactive astrocytes into functional motor neurons. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01815-y

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01815-y

Keywords: reactive astrocytes, motor neurons, transdifferentiation, neuroregeneration, glial scarring, gene therapy, cell fate conversion, neuroscience, spinal cord injury, neurodegenerative disease, cellular reprogramming, Experimental and Molecular Medicine